Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01962792 · ClinicalTrials.gov registry record · Phase 1
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT01962792 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 84 participants.
The verdict
NCT01962792, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2013-12 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01962792
The ClinicalTrials.gov registry entry for NCT01962792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01962792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01962792 about?
NCT01962792 is a clinical study titled "Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma". A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
What is the current status of trial NCT01962792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2013-12. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01962792?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01962792?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.